Viking Therapeutics (VKTX) Net Income towards Common Stockholders: 2014-2025
Historic Net Income towards Common Stockholders for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$90.8 million.
- Viking Therapeutics' Net Income towards Common Stockholders fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
- Per Viking Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$90.8 million for Q3 2025, which was down 38.52% from -$65.5 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Net Income towards Common Stockholders ranged from a high of -$12.4 million in Q4 2021 and a low of -$90.8 million during Q3 2025.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$25.0 million (2024), whereas its average is -$36.2 million.
- Data for Viking Therapeutics' Net Income towards Common Stockholders shows a maximum YoY crashed of 262.79% (in 2025) over the last 5 years.
- Quarterly analysis of 5 years shows Viking Therapeutics' Net Income towards Common Stockholders stood at -$12.4 million in 2021, then tumbled by 58.29% to -$19.6 million in 2022, then fell by 25.72% to -$24.6 million in 2023, then crashed by 44.00% to -$35.4 million in 2024, then crashed by 262.79% to -$90.8 million in 2025.
- Its last three reported values are -$90.8 million in Q3 2025, -$65.5 million for Q2 2025, and -$45.6 million during Q1 2025.